

---

## Oncopeptides Q3 2024 - Sluggish Growth

Redeye comments on Oncopeptides Q3 report 2024. Revenues in Q3 increased slightly compared to Q2, but product sales declined. Nevertheless, sales should improve in the next quarters as the Spanish launch gains pace.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

[Oncopeptides Q3 2024 - Sluggish Growth](#)